0000899243-20-013027.txt : 20200513 0000899243-20-013027.hdr.sgml : 20200513 20200513185053 ACCESSION NUMBER: 0000899243-20-013027 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200511 FILED AS OF DATE: 20200513 DATE AS OF CHANGE: 20200513 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sumitomo Chemical Co., Ltd. CENTRAL INDEX KEY: 0001798550 STATE OF INCORPORATION: M0 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 20874818 BUSINESS ADDRESS: STREET 1: 27-1, SHINKAWA 2-CHOME STREET 2: CHUO-KU CITY: TOKYO STATE: M0 ZIP: 104-8260 BUSINESS PHONE: 813-5543-5142 MAIL ADDRESS: STREET 1: 27-1, SHINKAWA 2-CHOME STREET 2: CHUO-KU CITY: TOKYO STATE: M0 ZIP: 104-8260 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dainippon Sumitomo Pharma Co Ltd CENTRAL INDEX KEY: 0001446601 STATE OF INCORPORATION: M0 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 20874819 BUSINESS ADDRESS: STREET 1: 60 WALL STREET CITY: NEW YORK STATE: NY ZIP: 10005 BUSINESS PHONE: 212-319-7600 MAIL ADDRESS: STREET 1: 60 WALL STREET CITY: NEW YORK STATE: NY ZIP: 10005 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sumitovant Biopharma Ltd. CENTRAL INDEX KEY: 0001798244 STATE OF INCORPORATION: D0 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37929 FILM NUMBER: 20874820 BUSINESS ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: (646) 802-3660 MAIL ADDRESS: STREET 1: C/O ROIVANT SCIENCES, INC. STREET 2: 320 WEST 37TH STREET, 5TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10018 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Myovant Sciences Ltd. CENTRAL INDEX KEY: 0001679082 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: CA FISCAL YEAR END: 0331 BUSINESS ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB BUSINESS PHONE: 44 207-400-3351 MAIL ADDRESS: STREET 1: SUITE 1, 3RD FLOOR STREET 2: 11-12 ST. JAMES SQUARE CITY: LONDON STATE: X0 ZIP: SW1Y 4LB 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-11 0 0001679082 Myovant Sciences Ltd. MYOV 0001798550 Sumitomo Chemical Co., Ltd. 27-1, SHINKAWA 2-CHOME CHUO-KU, TOKYO M0 104-8260 JAPAN 0 0 1 0 0001446601 Dainippon Sumitomo Pharma Co Ltd 6-8 DOSHOMACHI 2-CHOME CHUO-KU, OSAKA M0 541-0045 JAPAN 0 0 1 0 0001798244 Sumitovant Biopharma Ltd. 11-12 ST. JAMES'S SQUARE SUITE 1 3RD FLOOR LONDON X0 SW1Y 4LB UNITED KINGDOM 0 0 1 0 Common Stock 2020-05-11 4 P 0 35000 12.7824 A 48352693 I See Footnote Common Stock 2020-05-12 4 P 0 24448 13.5146 A 48377141 I See Footnote This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan"). The price reported in column 4 is the average stock price. Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,352,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. This acquisition of a total of 24,448 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan. Sumitovant directly owns 48,377,141 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein. Sumitomo Chemical Co., Ltd. By: /s/ Krunal Shah, as Attorney-in-Fact 2020-05-13 Sumitomo Dainippon Pharma Co., Ltd. By: Tsutomu Nakagawa, Senior Director, Global Corporate Strategy /s/ Tsutomu Nakagawa 2020-05-13 Sumitovant Biopharma Ltd. By: /s/ Krunal Shah, as Attorney-in-Fact 2020-05-13